Navlimetostat

N/A

Report date: 2026/05/25 20:02:40
NME

Base Information

Drug NameNavlimetostat
Drug Alias NameMRTX-1719BMS-986504
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionProtein arginine methyltransferase 5 inhibitors
TargetsProtein arginine methyltransferase 5
Therapy Area/IndicationsGastroesophageal Junction NeoplasmsSolid tumoursCarcinoma, Non-Small-Cell Lung +[14] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[40] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesMirati Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesBristol Myers Squibb SrlcompanyBristol-Myers Squibb (China) Investment Co LtdIvy Brain Tumor Center +[7] 
Inactive CompaniesN/A
Active IndicationsGastroesophageal Junction NeoplasmsSolid tumoursCarcinoma, Non-Small-Cell Lung +[13] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A